Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2

Status

Recruiting 36Completed 13Active not recruiting 13Terminated 7Unknown 4Not yet recruiting 4Withdrawn 3

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Carcinoma, Hepatocellular 4Small Cell Lung Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Liver Neoplasms 2Treatment-Refractory Solid Tumors 1Rare Tumour 1Neoplasm Metastasis 1Extensive Stage Lung Small Cell Cancer 1

Interventions

lenvatinib 16Bevacizumab 14sintilimab 11tislelizumab 9apatinib 8regorafenib 6donafenib 6camrelizumab 5atezolizumab 4Immune Checkpoint Inhibitors 4Hepatectomy 4durvalumab 3Radiosurgery 3Capecitabine 3spartalizumab 2pembrolizumab 2cabozantinib 2anlotinib 2Specimen Handling 2Oxaliplatin 2Observation 2Magnetic Resonance Spectroscopy 2Injections 2Immunotherapy 2Folfox protocol 2Fecal Microbiota Transplantation 2Electroporation 2Blood Specimen Collection 2ursodoxicoltaurine 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Hepatocellular × atezolizumab × Clear all
NCT07543510 2026-04-22

Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma

Third Affiliated Hospital, Sun Yat-Sen University

Phase NA Not yet recruiting
38 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07461675 2026-03-10

Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection

University of Geneva, Switzerland

Phase 3 Not yet recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07281664 2025-12-15

Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Third Affiliated Hospital, Sun Yat-Sen University

Phase NA Not yet recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06680258 2025-09-03

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Tempest Therapeutics

Phase 3 Not yet recruiting
740 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡